2023 World Conference on Lung Cancer (Posters)-P1.25. Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis

P1.25. Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis - PDF(Slides)

Back to course

Pdf Summary

This document discusses the use of complete pathologic response (pCR) as a surrogate endpoint in neoadjuvant immunotherapy clinical trials for early-stage non-small cell lung cancer (NSCLC). The study aims to evaluate the correlation between pCR and two-year event-free survival (EFS) in these trials. A meta-analysis of five randomized clinical trials and ten single-arm trials was conducted, involving a total of 2,343 patients. The results show a strong correlation between pCR and two-year EFS, indicating that pCR could potentially serve as a surrogate endpoint for EFS in neoadjuvant immunotherapy trials. However, the trial-level surrogacy was found to be moderate but imprecise. <br /><br />The document also highlights the need for more mature follow-up data and standardized trial procedures to reduce heterogeneity. It emphasizes the importance of standardizing the definition of pCR among different clinical trials in order to accurately evaluate its surrogacy for EFS. The study concludes that while pCR shows promise as a surrogate endpoint in neoadjuvant immunotherapy clinical trials for NSCLC, further research is needed to establish its validity and reliability in this context. <br /><br />Overall, this analysis provides valuable insights into the potential use of pCR as a surrogate endpoint in neoadjuvant immunotherapy trials for NSCLC and highlights the need for more standardized approaches in future studies.

Asset Subtitle

Jacobi Hines

Meta Tag

Speaker Jacobi Hines

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

complete pathologic response

pCR

surrogate endpoint

neoadjuvant immunotherapy

clinical trials

non-small cell lung cancer

NSCLC

event-free survival

EFS

meta-analysis